Chromatin Proteins and Transcription Factors as Therapeutic Targets: Volume 107

Chromatin Proteins and Transcription Factors as Therapeutic Targets: Volume 107

Series edited by 

Free delivery worldwide

Available. Dispatched from the UK in 1 business day
When will my order arrive?


Chromatin Proteins and Transcription Factors as Therapeutic Targets, the latest volume in the Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.
show more

Product details

  • Hardback | 386 pages
  • 152 x 229 x 22.35mm | 700g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0128123907
  • 9780128123904

Table of contents

1. Targeting Chromatin Remodeling in Inflammation and Fibrosis 2. HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell 3. Targeting IKK and NF- B for Therapy 4. NF- B as a Therapeutic Target in Inflammatory-Associated Bone Diseases 5. The Functional Stability of FOXP3 and ROR t in Treg and Th17 and Their Therapeutic Applications 6. The Complex Role of the ZNF224 Transcription Factor in Cancer 7. Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications 8. Transcription Factors as a Target for Vaccination Against Ticks and Mites 9. Elucidating the Mutational Landscape in Hepatocyte Nuclear Factor 1ss (HNF1B) by Computational Approach
show more

About Rossen Donev

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2010 Dr. Donev was appointed Senior Lecturer in Swansea University. Currently he is Head of Research at MicroPharm Ltd, UK and Director of Biomed Consult, UK. He has published more than 60 research papers, has chaired scientific meetings in Molecular Medicine and given plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on design of antibody-based oral treatment of pathological conditions of the colon and small intestines.
show more